Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
Close

Search

Subscribe
FDA rejects Capricor Duchenne therapy, a decision that was slow in coming
Business

FDA rejects Capricor Duchenne therapy, a decision that was slow in coming

jack colman
By jack colman
November 21, 2026 2 Min Read
Comments Off on FDA rejects Capricor Duchenne therapy, a decision that was slow in coming

Adam Feuerstein is a senior biotechnology writer and columnist, reporting on the intersection of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotechnology podcast The Readout Loud and author of the Adam’s Biotech Scorecard newsletter. You can reach Adam on Signal at stataf.54.

The Food and Drug Administration announced Friday that it has rejected a cell therapy for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.

The decision to prevent the treatment, called deramiocel, from marketing should have been an easy one for regulators to make. The targeted patient population – adolescents and young men with Duchenne who had already lost the ability to walk – have few treatment options today. Deramiocel didn’t help them either. Capricor conducted two randomized clinical trials. Both failed to demonstrate that deramiocel could prevent heart failure or preserve muscle function in their arms.

But nothing is simple when it comes to regulating medications for Duchenne, a progressive disease that causes muscle wasting.

Exclusive STAT+ story

Already have an account? Log in

STAT+

STAT+

This article is reserved for STAT+ subscribers

Unlock this article, plus in-depth analysis, newsletters, premium events and news alerts.

Already have an account? Log in

See all packages

To read the rest of this story, subscribe to STAT+.

Subscribe

Gn bussni

Views: 6
jack colman
Author

jack colman

**Jack** is a staff journalist and digital content writer at **DailyVoxa**, specializing in breaking news, technology, artificial intelligence, business, and global affairs. He is passionate about transforming complex topics into clear, accurate, and engaging stories that help readers stay informed.With a strong focus on fact-based reporting and thorough research, Jack monitors developing events, analyzes reliable sources, and delivers timely news with clarity and context. His work emphasizes accuracy, transparency, and editorial integrity while avoiding sensationalism.At DailyVoxa, every article written by Jack follows the publication's Editorial Policy, Fact-Checking Policy, and Ethics Policy. He is committed to providing trustworthy journalism that empowers readers with reliable information and meaningful insights into the stories shaping the world.

Follow Me
Other Articles
Bigfoot files quietly released by US Forest Service
Previous

Bigfoot files quietly released by US Forest Service

Lana Del Rey’s “Crazy for You” is officially released on GTA VI
Next

Lana Del Rey’s “Crazy for You” is officially released on GTA VI

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.
  • About Us
  • Accessibility Statement
  • Advertise With Us
  • AI Usage & Transparency Policy
  • Contact us
  • Cookie Policy
  • Corrections Policy
  • Meet Our Team
  • Privacy Policy
    • Disclaimer
    • DMCA & Copyright Policy
    • Editorial Policy
    • Ethics Policy
    • Fact-Checking Policy
  • Terms and Conditions
Copyright 2026 — Today's News. Tomorrow's Perspective.. All rights reserved.